Gautier S - Search Results

1

PPARs: a potential target for a disease-modifying strategy in stroke.

Ouk T, Potey C, Gautier S, Bastide M, Deplanque D, Staels B, Duriez P, Leys D, Bordet R. Ouk T, et al. Among authors: gautier s. Curr Drug Targets. 2013 Jun;14(7):752-67. doi: 10.2174/1389450111314070005. Curr Drug Targets. 2013. PMID: 23514380 Review.

2

[Concern of pharmacovigilance: proarrhythmic effects of medications in current use].

Caron J, Gautier S, Couderc E, Bordet R. Caron J, et al. Among authors: gautier s. Arch Pediatr. 1999;6 Suppl 2:231s-232s. doi: 10.1016/s0929-693x(99)80422-9. Arch Pediatr. 1999. PMID: 10370490 French. No abstract available.

3

Analysis of the direct cost of adverse drug reactions in hospitalised patients.

Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Bordet R, et al. Among authors: gautier s. Eur J Clin Pharmacol. 2001 Mar;56(12):935-41. doi: 10.1007/s002280000260. Eur J Clin Pharmacol. 2001. PMID: 11317484

4

The cost of adverse drug reactions.

Gautier S, Bachelet H, Bordet R, Caron J. Gautier S, et al. Expert Opin Pharmacother. 2003 Mar;4(3):319-26. doi: 10.1517/14656566.4.3.319. Expert Opin Pharmacother. 2003. PMID: 12614184 Review.

5

Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.

Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R. Gautier S, et al. Stroke. 2003 Dec;34(12):2975-9. doi: 10.1161/01.STR.0000101914.62066.7B. Epub 2003 Nov 13. Stroke. 2003. PMID: 14615621

6

The neuroprotective effect of the antioxidant flavonoid derivate di-tert-butylhydroxyphenyl is parallel to the preventive effect on post-ischemic Kir2.x impairment but not to post-ischemic endothelial dysfunction.

Pétrault O, Bastide M, Cotelle N, Gelé P, Gautier S, Laprais M, Vamecq J, Duriez P, Bordet R. Pétrault O, et al. Among authors: gautier s. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):395-403. doi: 10.1007/s00210-004-0966-x. Epub 2004 Oct 19. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15502971

7

Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion.

Pétrault O, Ouk T, Gautier S, Laprais M, Gelé P, Bastide M, Bordet R. Pétrault O, et al. Among authors: gautier s. Br J Pharmacol. 2005 Apr;144(8):1051-8. doi: 10.1038/sj.bjp.0706124. Br J Pharmacol. 2005. PMID: 15700030 Free PMC article.

8

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. Bordet R, et al. Among authors: gautier s. Biochem Soc Trans. 2006 Dec;34(Pt 6):1341-6. doi: 10.1042/BST0341341. Biochem Soc Trans. 2006. PMID: 17073815 Review.

9

Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.

Gautier S, Ouk T, Petrault O, Caron J, Bordet R. Gautier S, et al. Br J Pharmacol. 2009 Feb;156(4):673-9. doi: 10.1111/j.1476-5381.2009.00068.x. Epub 2009 Feb 4. Br J Pharmacol. 2009. PMID: 19210512 Free PMC article.

10

Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection.

Ouk T, Laprais M, Bastide M, Mostafa K, Gautier S, Bordet R. Ouk T, et al. Among authors: gautier s. Vascul Pharmacol. 2009 Nov-Dec;51(5-6):323-30. doi: 10.1016/j.vph.2009.08.002. Epub 2009 Sep 2. Vascul Pharmacol. 2009. PMID: 19732852

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

332 results

Search Page